Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boehringer Ingelheim Licenses Simcere’s SIM0709 Bispecific for Inflammatory Bowel Disease

Fineline Cube Jan 27, 2026
Company Deals

Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture

Fineline Cube Jan 27, 2026
Company Deals

HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing

Fineline Cube Jan 27, 2026
Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Fineline Cube Jan 26, 2026
Company Deals

GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing

Fineline Cube Jan 26, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline

Fineline Cube Jan 27, 2026
Company Drug

BioArctic Partner Eisai Submits EMA Application for Four-Week Lecanemab Dosing in Alzheimer’s

Fineline Cube Jan 27, 2026
Company Deals

Roche’s Genentech Partners with Peptidream for First-in-Class PDCs in Radioisotope Therapy

Fineline Cube Sep 21, 2023

Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has announced a partnership with Japan’s peptide-based...

Company Deals

Lynk Pharmaceuticals Secures Series C2 Financing to Advance pipeline

Fineline Cube Sep 21, 2023

Lynk Pharmaceuticals Co., Ltd, a China-based pharmaceutical company, has announced the successful completion of its...

Company Drug

Hainan Poly Pharm Submits DMF for Tecovirimat API to US FDA

Fineline Cube Sep 21, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced the filing of a Drug...

Company Legal / IP

South Africa’s Competition Commission Investigates J&J for MDR-TB Drug Pricing and Evergreening

Fineline Cube Sep 21, 2023

The Competition Commission of South Africa has announced an investigation into Johnson & Johnson (J&J;...

Company Drug

Tonghua Golden-Horse’s Octohydroaminoacridine Succinate Meets Phase III Endpoints in Alzheimer’s Disease

Fineline Cube Sep 21, 2023

China-based Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) has announced positive results from its...

Policy / Regulatory

China’s NHC Expands Rare Disease List, Includes 21 Cancer Types

Fineline Cube Sep 21, 2023

The National Health Commission (NHC) of China has released an updated national list of rare...

Company Drug

AIM Vaccine’s Serum-Free Rabies Vaccine Completes Phase III Safety Observation

Fineline Cube Sep 21, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the successful completion of the 7-day...

Company Drug Medical Device

Jiangsu Yahong’s Cevira Meets Primary Endpoint in Phase III Cervical HSIL Study

Fineline Cube Sep 21, 2023

Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments, has...

Company Drug

Hybio Pharmaceutical Gets NMPA Approval for COVID-19 Nasal Spray HY3000

Fineline Cube Sep 21, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has received approval from the National Medical Products...

Company Drug

GSK’s Ojjaara Approved by FDA for Anemic Myelofibrosis Patients

Fineline Cube Sep 20, 2023

The US Food and Drug Administration (FDA) has granted regulatory approval to GlaxoSmithKline (GSK; NYSE:...

Company Drug

BeiGene Regains Full Rights to Tislelizumab After Terminating Novartis Deal

Fineline Cube Sep 20, 2023

China-based biotech company BeiGene (NASDAQ: BGNE) has reached a mutual agreement with Novartis (NYSE: NVS)...

Company

Kinnate Biopharma Announces Restructuring and Job Cuts Amid Financial Pressures

Fineline Cube Sep 20, 2023

US-based Kinnate Biopharma Inc., (NASDAQ: KNTE), a company dedicated to the development of small-molecule cancer...

Company Drug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Approval for Two Novel Drug Candidates

Fineline Cube Sep 20, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced receiving...

Company Drug

Pfizer’s Cibinqo and Everest Medicines’ Cefepime-Taniborbactam Selected for Priority Reviews by CDE

Fineline Cube Sep 20, 2023

The Center for Drug Evaluation (CDE) has indicated on its website that Pfizer’s (NYSE: PFE)...

Company Drug

EMA’s CHMP Supports Gilead’s Veklury for COVID-19 Patients with Hepatic Impairment

Fineline Cube Sep 20, 2023

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recently...

Company Deals

Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors

Fineline Cube Sep 20, 2023

Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to...

Policy / Regulatory

NHSA Clears Retagliptin and Ambroxol for National Reimbursement Drug List Inclusion

Fineline Cube Sep 20, 2023

The National Healthcare Security Administration (NHSA) has completed a review of the National Reimbursement Drug...

Company Drug

FDA Grants Priority Review to MSD’s Welireg for Advanced RCC Indication Extension

Fineline Cube Sep 20, 2023

The US Food and Drug Administration (FDA) has granted priority review status to an indication...

Company Deals

Kangtai Biological Expands Global Reach with Varicella Vaccine Licensing Deals

Fineline Cube Sep 20, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a China-based biopharmaceutical company, has entered into...

Company Drug

Astellas Pharma’s Xtandi NDA for mHSPC Treatment Accepted by China’s CDE

Fineline Cube Sep 20, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...

Posts pagination

1 … 418 419 420 … 614

Recent updates

  • Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline
  • Bio-heart Secures Indonesia Approval for Iberis RDN System
  • BioArctic Partner Eisai Submits EMA Application for Four-Week Lecanemab Dosing in Alzheimer’s
  • Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy
  • ASCP Launches $250K Grants for mCRC Biomarker Testing with Pfizer, ASCO
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Aucta Pharma Files for Hong Kong IPO with CNS and Rare Disease Pipeline

Medical Device

Bio-heart Secures Indonesia Approval for Iberis RDN System

Company Drug

BioArctic Partner Eisai Submits EMA Application for Four-Week Lecanemab Dosing in Alzheimer’s

Company Drug

Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.